Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Suspended 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 24Myeloid 7Lymphoid 3Classical hematology 2Tumor-Agnostic 1Thoracic 1

Conditions

Hodgkin Disease 2Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cyclophosphamide 71Rituximab 53Specimen Handling 47Biopsy 40Doxorubicin 39Vincristine 38Magnetic Resonance Spectroscopy 36Prednisone 35venetoclax 28obinutuzumab 26fludarabine 26Methotrexate 22ibrutinib 21Cytarabine 21Dexamethasone 20Lenalidomide 19Etoposide 18merphos 17blinatumomab 17zanubrutinib 15prednylidene 15fludarabine phosphate 15deltacortene 15acalabrutinib 15X-Rays 14Mercaptopurine 14Bendamustine Hydrochloride 14pegaspargase 13Calcium Dobesilate 13Nivolumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Azacitidine × Lymphoid × 30 days × Clear all
NCT01333046 2026-06-03

TACTAL

Baylor College of Medicine

Phase 1 Active not recruiting
36 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT04803201 2026-06-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Suspended
170 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT05355051 2026-05-18

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

M.D. Anderson Cancer Center

Phase 2 Recruiting
24 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡